PeptiCRAd-1

Phase 1Small molecule

VValo Therapeutics Oy

PeptiCRAd-1 is one of 47 small molecule programs targeting Treatment. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TreatmentActive, not recruiting

TreatmentPhase 1

Active, not recruiting

Competition

Competitive Landscape

350 competitors in Treatment

#DrugCompanyPhaseTrials

Biltricide

Bayer

Preclinical

4 2

Dexilant

Takeda

Preclinical

2 3

Alfenta

Jazz Pharmaceuticals

Preclinical

1 4

Niclocide

Bayer

Preclinical

1 5

Minipress

Pfizer

Preclinical

1 6

Theo-Dur

Pfizer

Preclinical

1 7

Hivid

CConrado Roberto Hoffmann Filho

Preclinical

6 8

Aurlumyn

BBTG International Inc.

Preclinical

1 9

Lotemax

PPharmos

Preclinical

1 10

Norpramin

VValidus Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Treatment

NCT05492682

Clinical

Trials by Indication[1]

Treatment1 trial

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Active, not recruiting·VValo Therapeutics Oy·Phase 1·NCT05492682·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PeptiCRAd-1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PeptiCRAd-1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PeptiCRAd-1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Valo Therapeutics Oy company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: VValo Therapeutics Oy

PeptiCRAd-1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Treatment1 trial

References

Drug Info

Quick Facts

Related News